A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
← catalyst calendarNCT06145373 · readout in 648 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
2
Countries
Taiwan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-01 | actual | When the study began enrolling |
| Primary completion | 2028-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia A
Interventions
- Drug: Fitusiran (SAR439774) — also filed as SAR439774, Qfitlia®
- Biological: Clotting factor concentrates (CFC) or bypassing agents (BPA)
- Biological: Antithrombin concentrate (ATIIIC)
- Biological: Emicizumab
Primary outcome
what the primary-completion date above is the date OFNumber of participants with Adverse events (AEs) during the fitusiran treatment
measured From Day 1 up to Month 4
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed